Dow Up0.28% Nasdaq Up0.13%

Dyax Corp. (DYAX)

10.53 Up 0.01(0.10%) 10:31AM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Dyax Corp.
55 Network Drive
Burlington, MA 01803
United States - Map
Phone: 617-225-2500
Fax: 617-225-2501

Index Membership:N/A
Full Time Employees:120

Business Summary 

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which would be a candidate to prophylactically treat HAE and other PKM disorders. The company distributes KALBITOR through a network of wholesale and specialty pharmacy arrangements. It has agreements with CVie Therapeutics for the development and commercialization of KALBITOR in the treatment of HAE and other angioedema indications in China; and Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The company also has a strategic collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Dyax Corp.

Corporate Governance 
Dyax Corp.’s ISS Governance QuickScore as of Sep 1, 2014 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Henry E. Blair , 70
Co-Founder, Chairman of The Board and Member of Strategy & Science Committee
Mr. Gustav A. Christensen , 66
Chief Exec. Officer, Pres and Director
Mr. George V. Migausky , 59
Chief Financial Officer, Principal Accounting Officer and Exec. VP
Mr. Andrew D. Ashe , 47
Exec. VP and Gen. Counsel
Dr. Burt A. Adelman M.D., 61
Chief Medical Officer and Exec. VP of R&D
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders